Clinical Outcomes and Molecular Profile of Differentiated Thyroid Cancers With Radioiodine-Avid Distant Metastases
Open Access
- 1 May 2013
- journal article
- other
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 98 (5), E829-E836
- https://doi.org/10.1210/jc.2012-3933
Abstract
Background: Radioiodine (RAI) remains the mainstay of therapy for RAI-avid (RAIA) distant metastatic thyroid carcinoma. We previously demonstrated that RAI-refractory distant metastatic thyroid cancers commonly harbor BRAF mutations. However, the molecular profile of RAIA metastatic thyroid cancer is unknown. Here we describe the mutational profile of thyroid tumors from follicular cell-derived cancer (FCDTC) patients presenting with RAIA distant metastases. In addition, we aimed to correlate clinical outcomes of RAI therapy with clinicopathological factors and tumor mutational status. Methods: We retrospectively identified 43 patients with FCDTC who had RAI uptake in the lungs and/or bones on their initial 131I postablation scan. Primary tumors were genotyped for known mutations in thyroid cancer genes. Structural response to RAI was assessed 6–18 months after each administered RAI activity and at the end of follow-up. Results: RAS, BRAF, RET/PTC, and PIK3CA mutations were found in 42, 23, 10, and 2% of tumors, respectively, and the remaining 23% were wild type. None of these patients achieved cure after repeat RAI therapies, and most patients (54%) experienced disease progression despite repeated RAI administration. There was an increased prevalence of RAS mutations in these RAIA tumors. RAS-mutant cancers were more likely to concentrate iodine on diagnostic whole body scans. Despite this, structural response to RAI was not influenced by tumor genotype. Conclusions: RAIA metastatic FCDTC are overrepresented with RAS mutations, whereas RAI refractory metastatic thyroid cancers are enriched with BRAF mutations. Despite a seemingly preserved ability to concentrate iodine, RAI therapy is ineffective in achieving cure in most patients with RAIA metastatic FCDTC, even in RAS-mutant disease. These poor outcomes may be improved based on recent evidence that pretreatment with MAPK kinase 1/2 inhibitors enhances responses to RAI, particularly in patients with RAS-mutant tumors.This publication has 17 references indexed in Scilit:
- Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid CancerThe New England Journal of Medicine, 2013
- Improved RNA quality and TaqMan®Pre-amplification method (PreAmp) to enhance expression analysis from formalin fixed paraffin embedded (FFPE) materialsBMC Biotechnology, 2008
- Rearrangement Analysis in Archival Thyroid Tissues: Punching Microdissection and Artificial RET/PTC 1–12 TranscriptsJournal of Surgical Research, 2007
- Poorly Differentiated Thyroid Carcinoma: The Turin Proposal for the Use of Uniform Diagnostic Criteria and an Algorithmic Diagnostic ApproachThe American Journal of Surgical Pathology, 2007
- Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine TherapyJournal of Clinical Endocrinology & Metabolism, 2006
- Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosisCancer, 2006
- Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography ScanningJournal of Clinical Endocrinology & Metabolism, 2006
- PAX8-PPARγ Rearrangement in Thyroid TumorsThe American Journal of Surgical Pathology, 2002
- Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroidThe American Journal of Surgery, 1996
- Long-Term Results of Treatment of 283 Patients with Lung and Bone Metastases from Differentiated Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 1986